Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 188Thoracic 145Lymphoid 35Sarcoma 17Other solid neoplasm 14Gynecologic 14Genitourinary 12Gastrointestinal 9CNS 9Tumor-Agnostic 5Other hematologic neoplasm 5Plasma cell 4Dermatologic 3Endocrine 2NET 1Head & Neck 1

Conditions

Multiple Myeloma 4Neoplasms, Plasma Cell 1Leukemia 1Amyloidosis 1

Interventions

Dexamethasone 871Bortezomib 457Lenalidomide 456Cyclophosphamide 365Melphalan 272Calcium Dobesilate 263daratumumab 234pomalidomide 208carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 57Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Vinorelbine × Plasma cell × Clear all
NCT03442673 2025-03-28

MOCCCA

Insel Gruppe AG, University Hospital Bern

Phase 2 Completed
137 enrolled
Plasma cell

Multiple Myeloma

NCT02791373 2018-04-03

ViGeM

Insel Gruppe AG, University Hospital Bern

Phase 2 Completed
136 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma

NCT00477035 2017-01-11

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Stanford University

Phase 1 Completed
22 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Multiple Myeloma

NCT01220375 2014-04-17

PAV

Insel Gruppe AG, University Hospital Bern

Phase 2 Completed
44 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡